Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
about
Episodic therapy for recurrent genital herpes in non-immunocompromized adultsApical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug targetAbsence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected miceMolecular Basis of Prodrug Activation by Human Valacyclovirase, an -Amino Acid Ester HydrolaseAmino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in RatsWhat is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.Antiviral selection in the management of acute retinal necrosis.Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal functionValacyclovir and acyclovir pharmacokinetics in immunocompromised children.Controlled ex-vivo plasma hydrolysis of valaciclovir to acyclovir demonstration using tandem mass spectrometry.Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapyValaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study GroupValaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study GroupRecent advances in management of genital herpes.Effect of high versus low oral doses of valacyclovir on herpes simplex virus-1 DNA shedding into tears of latently infected rabbits.Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.Valacyclovir in the treatment of acute retinal necrosis.Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.Disposition kinetics of a dipeptide ester prodrug of acyclovir and its metabolites following intravenous and oral administrations in rat.Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster.Valacyclovir for the treatment of genital herpes.High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies.[Therapy refractory stromal Herpes keratitis under aciclovir].Valacyclovir for herpes simplex encephalitis.Oral antivirals for the acute treatment of recurrent herpes labialis.Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxinEnhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirinContemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: Four approved indications and 13 off-label uses.Main adult herpes virus infections of the CNS.Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.Chemical modification and formulation approaches to elevated drug transport across cell membranes.Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice.Pharmacokinetics of Stereoisomeric Dipeptide Prodrugs of Acyclovir Following Intravenous and Oral Administrations in Rats: A Study Involving In vivo Corneal Uptake of Acyclovir Following Oral Dosing.Exploitation of bile acid transport systems in prodrug design.TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs.Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice.Evolution of an amino acid based prodrug approach: stay tuned.Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine
P2860
Q24187642-4E6B8A8C-4DDD-4BB9-A188-BDF245A46BFDQ24655792-8F29E15A-A6E9-4964-BD62-73BBB8CCB5D9Q24797196-ECE281DB-5F70-48E8-A0B8-FD2B0A8D3B06Q27649800-80C7DE21-1BFE-48FA-8888-86D7D5F9DDABQ28548007-625FB261-7AD5-4A90-B5B5-F423F6C92A9DQ33278984-48C760E4-7879-4BAB-A67A-2D76BC4BBDD2Q33644146-E898D479-7AAD-48E0-8D36-96D601387C13Q33676105-208E5A87-2EB1-4037-A448-42047CDB9D76Q33776931-3F9BDDD0-2E5E-45AE-8D6E-A7719B11DBC4Q33844972-3AA6D23D-84B3-4A92-95E4-8AB2B75965B2Q33884052-0A28B29C-5FDD-47AF-956B-267EB3BE3532Q33914361-1418E3E2-4460-4E1E-8415-D84FBCEC6CF4Q33936572-A8DE6C5C-29C7-425D-A159-3C9517A47122Q33936578-C46EBBDE-6C32-42A7-B46B-FBA553756EC1Q34012149-BC398DAE-B461-485B-A159-B370C332EB2EQ34135575-462938AC-1725-4DB1-9ADD-BFD05503AE1CQ34168234-202C031C-3250-49F5-A693-C67A28B81C57Q34403015-B0553797-DE13-44B8-8BD0-3C35C6644E98Q34408370-191E5A30-4A82-4B80-9CBA-68EBF6E1941FQ34530168-85329BCB-978B-4C39-ADFD-50EF2056CCC6Q34551831-938DC505-88DA-4E4F-9A97-9C448ED9A003Q34568338-5AD36FBF-703F-47CF-9569-9F0E88A3A53EQ34734868-2B705B8A-8DA9-44F3-AB8D-A7D43BD80EDDQ34991654-A3B013C7-0CCC-4540-BADF-F09E10C4D8E3Q35065826-FEE07F6C-2583-416C-84E3-BE69B16BA97AQ35668756-20022FA0-8AA9-408A-848B-0348F000CCE0Q35803128-A4453020-271C-4045-A59C-3AB6A0D004ACQ35831312-D4C5675C-E3FA-4D21-8A1D-98B912BA3802Q35941302-B274EF6A-D04B-46D9-B94B-D1C5212C3D12Q36170672-11239C42-C6FD-4232-ACE9-779B6A269F37Q36233543-E9FECF9F-AB47-4228-9DA3-8B381F24DEC1Q36401565-B3ED2585-B4D7-4B5B-BA29-46232E9342E1Q36527751-1374366E-928F-47FD-BFDA-2B39A4D97946Q36642360-921E1D34-8CB6-443C-897B-6ADE2FF7FC1CQ36866755-B13269B4-99F3-47A0-AD8B-43E7666A6F41Q36981149-617E4C1E-2018-4A4B-82F9-59207C5674A7Q37148469-E291C4A5-FCBD-407C-A3A8-7BA589E197C4Q37193116-650ABB4A-4EC6-44B8-905B-6EFC127F4FE8Q37210087-BF932953-1816-48FF-AAC0-6D471AA2AEE2Q37214548-74AE8E89-FA09-44DD-BE21-AD1861F6E4DF
P2860
Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Absolute bioavailability and m ...... oral administration to humans.
@ast
Absolute bioavailability and m ...... oral administration to humans.
@en
type
label
Absolute bioavailability and m ...... oral administration to humans.
@ast
Absolute bioavailability and m ...... oral administration to humans.
@en
prefLabel
Absolute bioavailability and m ...... oral administration to humans.
@ast
Absolute bioavailability and m ...... oral administration to humans.
@en
P2093
P2860
P356
P1476
Absolute bioavailability and m ...... oral administration to humans.
@en
P2093
P2860
P304
P356
10.1128/AAC.39.12.2759
P407
P577
1995-12-01T00:00:00Z